Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
Erenumab by Amgen for Pain: Likelihood of Approval
Erenumab is under clinical development by Amgen and currently in Phase II for Pain. According to GlobalData, Phase II drugs...
Data Insights
Erenumab by Amgen for Rosacea: Likelihood of Approval
Erenumab is under clinical development by Amgen and currently in Phase II for Rosacea. According to GlobalData, Phase II drugs...